Zhengye Biotechnology Holding Limited (NASDAQ:ZYBT – Get Free Report) saw a large growth in short interest in the month of July. As of July 31st, there was short interest totaling 296,924 shares, a growth of 417.6% from the July 15th total of 57,363 shares. Approximately 0.6% of the shares of the company are sold short. Based on an average daily volume of 19,111,558 shares, the short-interest ratio is presently 0.0 days.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings raised shares of Zhengye Biotechnology from a “sell (d-)” rating to a “sell (d)” rating in a report on Monday, July 20th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Sell”.
View Our Latest Analysis on ZYBT
Institutional Trading of Zhengye Biotechnology
Zhengye Biotechnology Price Performance
Shares of ZYBT stock traded up $0.01 during trading hours on Friday, hitting $1.53. 40,569 shares of the company were exchanged, compared to its average volume of 2,211,719. The company has a current ratio of 1.14, a quick ratio of 0.82 and a debt-to-equity ratio of 0.03. The firm has a fifty day simple moving average of $1.23 and a 200 day simple moving average of $1.02. Zhengye Biotechnology has a 52-week low of $0.62 and a 52-week high of $13.08.
About Zhengye Biotechnology
Zhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China.
See Also
- Five stocks we like better than Zhengye Biotechnology
- Joint Operations: Curaleaf Makes a Play for Aurora Cannabis
- Cerebras Sells Off After Earnings: Is This a Market Disconnection?
- Is Lockheed Martin Gearing Up to Lead Defense Stocks?
- Inside Teledyne’s Bold Bet on the Future of Medical Imaging
Receive News & Ratings for Zhengye Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zhengye Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
